Global Intravenous Anticoagulants Market Anticipated to Reach US$ 22,682.0 Million by 2031

According to a recent market study published by Growth Market Reports, titled, “Global Intravenous Anticoagulants Market By Type, By Application, By End-use and By Region: Size, Share, Trends and Opportunity Analysis, 2016-2031”, the market was valued at US$ 13,479.9 Million in 2022 and is anticipated to expand at a growth rate of 5.96% by 2031.

Get Sample Report @ https://growthmarketreports.com/request-sample/6105

Intravenous anticoagulants work by interrupting the action associated with the formation of blood clots. These are also called blood thinning medicines; however, they do not make the blood thinner. Even though intravenous anticoagulants are used for similar purposes, they are different from antiplatelet drugs, including low-dose aspirin and clopidogrel.

The global Intravenous Anticoagulants market has been segmented in terms of type, application, end-use, and region. In terms of type, the global Intravenous Anticoagulants market is split heparin, fondaparinux, and direct thrombin inhibitors.

On the basis of application, the market is fragmented into is unfractionated heparin (UFH), low molecular weight heparin (LMWH), fondaparinux, and direct thrombin inhibitors.

Based on end-use, the market is divided into hospitals, clinics, and ambulatory centers. Considering regions, the market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

The COVID-19 pandemic had a considerable impact on various markets, including the Intravenous Anticoagulants market. The Panel recommended that hospitalized COVID-19 patients who exhibit fast deterioration of pulmonary, cardiac, or neurological function or sudden, localized loss of peripheral perfusion required to be evaluated for thromboembolic illness. The Panel further recommended that COVID-19 patients who are highly suspected of having thromboembolic illness required to be treated with therapeutic anticoagulation, if diagnostic imaging is not possible.

Key Takeaways from the Study:

• Players in the global Intravenous Anticoagulants market include Abbott, AstraZeneca, B. Braun SE, Baxter International Inc., Bayer AG, Bristol-Myers Squibb Company, Fresenius SE & Co. KGaA., GSK plc, Johnson & Johnson, Novartis AG, Pfizer Inc., and Viatris Inc. These players held a major share of the global Intravenous Anticoagulants market in 2022.

• Rise in Prevalence of Deep Vein Thrombosis is key factors that drive the Intravenous Anticoagulants market.

• Increase in Outpatient Management of Anticoagulation Therapy is expected to create opportunities in the coming years.

• Based on type, the market is segmented into heparin, fondaparinux, and direct thrombin inhibitors. The heparin segment is expected to hold a considerable share of the market during the forecast period, as the anticoagulant effect of heparin is rapidly reversed using protamine sulfate. This is a critical advantage in situations where immediate cessation of anticoagulation is needed, such as during surgery or if there is excessive bleeding.

• Based on application, the market is segmented into is unfractionated heparin (UFH), low molecular weight heparin (LMWH), fondaparinux, and direct thrombin inhibitors. The unfractionated heparin (UFH) segment is anticipated to expand at a lucrative CAGR during the forecast period. The carotid artery sub-segment held significant value share of the market in 2022. Continuous monitoring of coagulation parameters, such as activated clotting time (ACT), is common during carotid endarterectomy. The dosage of UFH is adjusted during the procedure to maintain the desired level of anticoagulation, allowing real-time response to the patient’s condition.

• Based on the end-use, the market is segmented into hospitals, clinics, and ambulatory centers. The hospitals segment is anticipated to expand at a significant CAGR during the forecast period. The clinics segment held considerable share in 2022, owing to the rising incidence of atrial fibrillation (AF). Additionally, patients are leaning towards Anticoagulation Clinics (ACs) for treatment anticoagulation therapy.

• For instance, according to an estimation published by American Heart Association in 2021, atrial fibrillation is expected to affect 12.1 million people in the US by 2031, which is more than double the number in 2010.

• Based on regions, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Europe accounted for a significant share of the market in 2022, owing to the increasing healthcare spending in the region, backed with high availability of healthcare facilities, which, in turn, fuel the accessibility of intravenous anticoagulants.

• For instance, as per ONS (Office for National Statistics), spending on healthcare in the UK in 2022 was about USD 349 billion, including both government and non-government spending, which is an increase in nominal terms of about 0.7% from spending in 2021.

Scope of the Intravenous Anticoagulants Market Report:

Target Audience:

• Supply-side: Vendor, Manufacturer, Distributors, Supplier, Retailer.

• Regulatory Side: Concerned government authorities, and other approved regulatory bodies.

• Food Drug Administration (FDA)

• American College of Chest Physicians (ACCP)

• Novartis Institutes for BioMedical Research (NIBR)

• National Library of Medicine (NLM)

• Office for National Statistics (ONS)

• World Health Organization (WHO)

• National Health Commission (NHC)

• Centers for Disease Control and Prevention (CDC)